Group cognitive behavioural therapy of physical and psychological menopausal symptoms of Chinese women, delivered via Internet and mobile phone versus face to face: A protocol for a randomized non-inferiority trial

Dan Li, Jing Kong, Ying Yang, Suli Wang, Jiangping Wu, Jianqian Chao

Abstract

Background: Menopause syndrome generally includes psychological problems. Group treatment delivered via the Internet and mobile phone (imGT) may improve women’s physiological and psychological conditions.

Objective: To investigate the efficacy of group cognitive behavioural therapy of menopause-related mood swings and quality of life, delivered face to face or via the Internet and mobile phone.

Methods: This protocol is for a randomized controlled clinical trial with a sample of 140 menopausal women divided into 2 groups: imGT and face-to-face group treatment (fGT). The primary outcome will be the improvement in the menopausal symptoms of the two groups, as assessed by the Greene Climacteric Scale. The secondary outcomes will be: quality of life, assessed by the Short Form 36 Health Survey Questionnaire; insomnia, assessed by the Pittsburgh Sleep Quality Inventory; anxiety, assessed by the Hamilton Anxiety Rating Scale; and therapeutic alliance, assessed by the Working Alliance Inventory-Short Revised and Client Satisfaction Questionnaire-8. imGT will be performed once a week for 1.5 h for 10 weeks. All outcomes will be assessed at baseline, at a post-intervention evaluation (week 10), and at a follow-up evaluation (week 22).

Discussion: This study will be the first clinical trial to examine the effects of imGT on menopausal women in China. If imGT is found to be non-inferior to fGT, it will facilitate access to menopausal health services.

1. Introduction

Menopause is accompanied by multidimensional alterations that affect women’s quality of life [1]. These changes put women at high risk of health problems, both physical, such as hot flashes, night sweats and sleep disturbance [2–4], and psychological, such as anxiety [4,5]. It is estimated that, by 2030, in China, the number of women over 50 will have increased to more than 280 million [6]. Currently, 51%–55% of women in China experience menopause syndrome [7,8] with hot flashes (62%), fatigue (82%) [9], sleep disturbance (51%) and mood swings (40%) [10]. Mood swings affect not only mental health but also neurocognitive and cardiometabolic function [11]. Medical treatment, such as hormone replacement therapy, is effective in alleviating menopausal symptoms; however, several epidemiological studies have confirmed that the side-effects can include increased risk of breast cancer [12,13] and ovarian cancer [14]. Therefore, non-medical therapy should be investigated for menopausal symptoms.

Group treatment (GT), and in particular cognitive behavioural therapy (CBT), has been shown to have advantages in the treatment of anxiety [15–18], depression [19], posttraumatic stress disorder [20], and chronic pain [21]. A systematic review of 26 randomized controlled trials (RCTs) indicated that CBT can be beneficial for alleviating menopausal vasomotor symptoms [22]. Moreover, CBT was more effective for somatic symptoms when it was delivered as a group treatment (−4.43, 95% CI: −8.47 to −0.39; p < 0.05) than as an individual treatment (−1.00, 95% CI: −1.90 to −0.10; p < 0.05) [23]. However, there is limited evidence regarding the efficacy of GT for menopausal women [24,25]. Green [26] reported that 8 participants with menopausal symptoms improved on measures of hot flashes (t(7) = 3.4, p = 0.01), depression (t(7) = 3.7, p = 0.00), anxiety (t(7) = 4.2, p = 0.00), and quality of life (t(7) = −3.5, p = 0.01) after 10 sessions (2 h each) of GT. Ayers [27] reported that compared with a no...
treatment control condition (n = 45), GT (n = 48) significantly reduced the frequency of night sweats (mean SD, 1.33; 95% CI, 0.54–2.13; P = 0.001) after 4 weeks of intervention (2 h once a week), and mood and quality of life also improved.

However, GT typically faces problems such as long waiting times and restricted access [28]. It is also costly for patients to adhere to face-to-face GT [29]. Furthermore, in China, maternal and paediatric hospitals constitute only 0.3% of all medical institutions [30], which means there are limited health resources for menopause syndrome and related mood swings.

To improve access to services, psychotherapeutic interventions delivered via the Internet and mobile phone (IM) have been studied in recent years for conditions such as anxiety [31] and insomnia [32]. The benefits of IM therapies include robust adherence [33,34], cost-effectiveness [35], and an increase in acceptance of a mental health intervention [36]. A meta-analysis of 13 RCTs (participant count 31–201) found that Internet-delivered cognitive behavioural therapy (ICBT) and face-to-face treatment produce equivalent overall effects for psychiatric and somatic disorders, with a pooled effect size (Hedges’ g) at post-treatment of − 0.01 (95% CI: − 0.13 to 0.12) [37]. Further meta-evidence reveals that, compared with the control group at post-intervention among postpartum women, therapist-supported iCBT significantly improves stress (d = 0.84, n = 5), anxiety (d = 0.36, n = 6), and depressive symptoms (d = 0.63, n = 8) [38].

Beyond the academic context, menopausal women may benefit from guided GT or IM therapies due to their feasibility and accessibility. However, no studies have investigated the efficacy of GT with IM for menopause syndrome and its related mood swings. There are also no reports of the effect size of GT with IM.

Therefore, the aim of this study is to compare the efficacy of a group treatment delivered via Internet and mobile phone (imGT) with that of guided face-to-face group treatment (ffGT) for menopausal women with mood swings. We will conduct an RCT comparing the two treatment groups at baseline, at different time points throughout the trial, and at 3-month follow-up. The primary outcome of this study is the status of menopausal symptoms. The secondary outcomes are menopause-related mood swings, including anxiety, insomnia, and menopause-related quality of life (QOL). It is hypothesised that after 10 weeks of intervention, the imGT group will show non-inferiority overall effects on menopause symptoms compared with the ffGT group, especially on hot flushes and mood swings.

The intervention adherence of both groups will be determined by the number participants who complete the entire intervention. This is the first trial in China to evaluate menopause treatment using imGT and ffGT. Adverse events will be evaluated and recorded.

2. Method

2.1. Trial design

This is a protocol for a single-site, non-blinded RCT with two conditions in a 1:1 allocation: (1) group treatment delivered via the Internet and mobile phone (imGT) and (2) guided face-to-face group treatment (ffGT).

The trial will be reported consistent with the Consolidated Standards of Reporting Trials guidelines for RCTs [39] and the guidelines for Internet intervention trials [40]. This protocol has been approved by the Affiliated Obstetrics and Gynaecology Hospital of Nanjing Medical University in 2018 (NFLZ-2018-106). The results will be published according to the CONSORT statement in peer-reviewed journals. The trial has been registered at ClinicalTrial.gov (NCT03948289), which is a primary registry of the International Clinical Trial Registry Platform of the World Health Organization. The overall study design is illustrated in Fig. 1.
Participants assigned to fffGT therapy have to refuse other psychological treatment for the duration of the study.

2.5. Compliance and attrition

Therapy compliance will be assessed by the number of participants who complete the treatment modules. To enhance compliance, we will offer instant consultation about participants’ menopausal symptoms through the WeChat app for the imGT group or by telephone for the fffGT group. The imGT intervention will be recorded both online and offline by video, audio or pictures, while the fffGT intervention will be recorded by video. Both treatments can be accessed by an external panel to ensure adherence to the treatment protocol. Interventions will be discontinued upon participant request. When there is poor compliance or dropout, the reason will be sought and recorded if possible.

2.6. Assessment and outcome measures

For both imGT and fffGT, assessment will be conducted at baseline (T0), at completion of the intervention (10 weeks, T1), and at 12-week follow-up after the 10th intervention (T2). The trial will collect patient-reported outcome (PRO) data. T1 is set to be the principal time point, to avoid the risk of multiple statistical testing. Table 2 presents a list of

Table 1

<table>
<thead>
<tr>
<th>Module</th>
<th>Psychotherapeutic technique</th>
<th>Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goal setting</td>
<td>Psychological support therapy</td>
<td>Introduction, psychometric assessments, goal setting, treatment agenda</td>
</tr>
<tr>
<td>Menopause education</td>
<td>Psychological support therapy; Cognitive behavioural therapy</td>
<td>Discussion of homework assignments, menopause introduction, psycho-education</td>
</tr>
<tr>
<td>Sleep and relax</td>
<td>Mind-body relaxation therapy</td>
<td>Discussion of homework assignments, discussion of reasons for insomnia</td>
</tr>
<tr>
<td>Healthy attitudes</td>
<td>Psychological support therapy; Cognitive behavioural therapy</td>
<td>Discussion of homework assignments, identification of personal values and barriers</td>
</tr>
<tr>
<td>Stress tolerance</td>
<td>Music therapy; Breathing therapy</td>
<td>Discussion of homework assignments, discussion of reason for stress, problem-solving, diary writing</td>
</tr>
<tr>
<td>Lifestyle education</td>
<td>Psychological support therapy; Cognitive behavioural therapy</td>
<td>Discussion of homework assignments, lifestyle education, planning diet and physical exercise</td>
</tr>
<tr>
<td>Relationship management</td>
<td>Cognitive behavioural therapy; Role play</td>
<td>Discussion of homework assignments, communication training, sharing life experiences</td>
</tr>
<tr>
<td>Mood management</td>
<td>Breathing therapy; Psychological support therapy</td>
<td>Discussion of homework assignments, emotion control, write out feelings</td>
</tr>
<tr>
<td>Review and summary</td>
<td></td>
<td>Discussion of homework assignments, repeat of psychometrics</td>
</tr>
<tr>
<td>Share and future</td>
<td></td>
<td>Talking about successful experiences, future planning, future directions</td>
</tr>
</tbody>
</table>
Table 2

<table>
<thead>
<tr>
<th>Instrument</th>
<th>items</th>
<th>Weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Menopause symptoms</td>
<td>GCS²</td>
<td>x</td>
</tr>
<tr>
<td>Quality of life</td>
<td>SF-36³</td>
<td>x</td>
</tr>
<tr>
<td>Insomnia</td>
<td>PSQI⁴</td>
<td>x</td>
</tr>
<tr>
<td>Anxiety</td>
<td>HAM-A⁵</td>
<td>x</td>
</tr>
<tr>
<td>Therapeutic alliance</td>
<td>WAI-SR⁶</td>
<td>x</td>
</tr>
<tr>
<td></td>
<td>GSQ⁷</td>
<td>x</td>
</tr>
</tbody>
</table>

1. Greene Climacteric Scale.
2. The Short Form 36 Health Survey Questionnaire.
3. Pittsburgh Sleep Quality Index.
4. The Hamilton Anxiety Rating Scale.
5. The Working Alliance Inventory-Short Revised.

outcomes and measurements.

2.7. Primary outcome

The Greene Climacteric Scale (GCS) [45] is used for evaluating menopausal symptoms. It contains 21 questions covering 5 domains: anxiety, depression, somatic symptoms, vasomotor symptoms, and sexual function. Each question is answered on a 4-point Likert scale. The answers to all 21 questions are summed to give a total quality-of-life measure; a higher score indicates a worse quality of life. According to the hypothesis and the PRO-specific life measure; a higher score indicates a worse quality of life. The standard deviation is estimated to be 9 units [58]. We assume the non-inferiority margin of d = 0.6 effect sizes. For a mixed-linear model, there is no available software to calculate the sample size for analysis, and so an f index of 0.3 is used as a substitute for an effect size of 0.6 (Cohen’s d). Thus, with a statistical power of 0.80 and an alpha level of 0.05, the minimum sample size should be approximately 116 (58 for each group). Considering the attrition rates of previous trials, a 20% dropout rate [59] can be expected for this study, so the required sample size is 140 (70 per group).

2.10. Sample size estimation

Power estimation is based on the primary hypothesis regarding changes in menopausal symptoms measured with the Greene Climacteric Scale. According to previous research, iCBT group showed an effect size of 0.63 for hot flush, and 0.33 for overall menopausal symptoms. The standard deviation is estimated to be 9 units [58]. We assume the non-inferiority margin of d = 0.6 effect sizes. For a mixed-linear model, there is no available software to calculate the sample size for analysis, and so an f index of 0.3 is used as a substitute for an effect size of 0.6 (Cohen’s d). Thus, with a statistical power of 0.80 and an alpha level of 0.05, the minimum sample size should be approximately 116 (58 for each group). Considering the attrition rates of previous trials, a 20% dropout rate [59] can be expected for this study, so the required sample size is 140 (70 per group).

2.11. Randomization procedure

Eligible participants will be randomized to either the imGT or the fGT group after baseline data collection. Randomization and allocation will be conducted by a statistician not involved in the trial. For randomization, a computer algorithm with permuted block sizes (ranging from 2 to 8) will be used to ensure balanced group sizes of 1:1 and allocation concealment. The procedure will be conducted at http://www.randomization.com. The randomization will not have any stratification factors. After the baseline measurement, the participants who consent to be involved in the trial will receive an opaque envelope containing a randomized code for group allocation. Due to the nature of the intervention, blinding of the therapist and participants is not possible within the course of the study. Data will be recorded on separate data sheets by someone not involved in the study; hence, the data will be analysed without information regarding group allocation.

2.12. Data collection and management

Outcome data will be assessed via self-report using a secure online survey platform (www.wjx.cn). Participants will be recommended to finish the questionnaires in hospital or at home, and they will be reminded by instant message, email and phone call, to avoid missing data. Only the study team can access the information from this study; information will be saved in local, password-protected data files. We will back up the primary database weekly. The data will be monitored by physicians across the trial so that they can respond if a participant’s clinical symptoms worsen. A unique identification number will be given to each participant so that no individual subjects can be identified.

2.13. Statistical analysis

No interim data will be analysed during the trial. Intention-to-treat (ITT) samples will be analysed to evaluate the efficacy of the imGT and fGT interventions. Mixed-effects models (random intercept) [60] with interaction effects of group and time will be conducted on primary and secondary outcomes. Time, imGT group, baseline Greene Climacteric Scale score, and age will be included as covariates at randomization. Such a model can take account of the multiple time points for data collection and is reasonably robust to missing data, especially with a restricted maximum likelihood approach for a small sample size [61]. Multiple regression models will be used to test potential mediating or
moderating effects. The therapeutic alliance and treatment satisfaction questionnaires will be analysed using t-tests. According to the pattern of missing data, strategies will be evaluated to judge possible bias [62].

Complier average causal effect (CACE) analysis will be conducted to estimate the degree of protocol compliance within the intervention arms [63]. CACE analysis can also be used to compare the treatment effect between those who complied with treatment and those who would have complied if given the opportunity [64]. In this analysis, “full” participation is defined as going to at least five of the ten sessions for both imGT and fGT groups, which is the minimum number of attendances to benefit from the programme [65]. For the fGT group, completing 49 of the 70 everyday Punched-in is defined as full participation [66].

Sensitivity analysis will be conducted under the missing-at-random scenarios to examine bias. All analyses will be conducted with a two-sided level of significance (α = 0.05). Stata SE 15.0 software (Stata Corp LLC) will be used for data analysis. If there is no significant effect on the primary outcome and the estimated effect size is less than 0.6, explanatory analysis will be conducted to determine potential reasons for the null findings, such as poor adherence or heterogeneity effects.

3. Discussion

The aim of this study is to verify the feasibility and effects of imGT on menopausal syndrome, mood swings, and quality of life in menopausal women. There have been few studies on imGT [67–70], and none has focused on menopausal imGT. If imGT is found to be non-inferior to fGT, it could help menopausal women and possibly also their families. Moreover, because of the wide use of the WeChat app, imGT is a feasible and cost-effective way to conduct group therapy without regard to participants’ travel time.

Systematic reviews and meta-analyses have verified the ability of CBT to improve the physical and mood symptoms of menopausal women [27,71–73]. However, in the field of menopause, GT has not been well studied, especially in relation to effect size, interventional contents, adherence, and limitations. Thus, this RCT is designed to investigate the effect size of imGT and fGT.

The limitations of our study design are as follows. First, for imGT, there are two components of the intervention: a group treatment once a week and everyday daily Punched-in. It is difficult to determine which component is more important or if the two components complement each other. Second, blinding is not possible for the clinical assessment. This is a general problem in CBT. Third, the assessment and treatment of imGT are conducted via mobile phone, and they may therefore be affected by the phone or network environment. Finally, self-report scales are used to assess menopause and its related mood swings, which may cause participant recall bias as a systematic error.

The results of this study will be published in journals and presented at conferences. Future research could focus on the cost-effectiveness of imGT and fGT. We are also planning to develop a brief questionnaire to evaluate imGT to increase knowledge and awareness of menopausal group therapy.

4. Trial status

This study is currently in the recruitment stage, and pre-intervention assessments are being made.

Contributors

Jianqian Chao revised the paper.
Dan Li drafted the manuscript and contributed to specific aspects of the patient-reported outcome of the trial protocol.
Jing Kong contributed to specific aspects of the patient-reported outcome of the trial protocol, sourcing funding, and quality control.
Ying Yang is responsible for the psychological intervention.
Suli Wang is responsible for the psychological intervention.
Jiaping Wu is the director of department of maternal health who manages the program.
All the authors conceived and designed the study.

Funding

This trial is supported by the Nanjing Medical Science and Technology Development Fund (Grant No. YKK16196).

Ethical approval

This protocol was approved by the Affiliated Obstetrics and Gynecology Hospital of Nanjing Medical University in 2018 (NFLZ-2018-106).

Provenance and peer review

This article has undergone peer review.

Research data (data sharing and collaboration)

According to the data sharing statement policy of International Committee of Medical Journal Editors, individual participant data will be available including data dictionaries. All of the individual participant data collected during the trial will be shared after deidentification. Research documents will be available following publication (no end data) to anyone who wishes to access the data. These include Study protocol, Statistical Analysis Plan and Analytic Code. Requests should be directed to 2301792696@seu.edu.cn.

Declaration of Competing Interest

The authors declare that they have no conflict of interest.

Acknowledgements

The authors are grateful to the Affiliated Obstetrics and Gynecology Hospital of Nanjing Medical University, and to the department of maternal health for providing the rooms for intervention, and to American Journal Experts in the language editing work.

References


